The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders
Abstract
Background: The Royal Australian and New Zealand College of Psychiatrists is coordinating the development of clinical practice guidelines (CPGs) in psychiatry, funded under the National Mental Health Strategy (Australia) and the New Zealand Health Funding Authority. This paper presents CPGs for schizophrenia and related disorders. Over the past decade schizophrenia has become more treatable than ever before. A new generation of drug therapies, a renaissance of psychological and psychosocial interventions and a first generation of reform within the specialist mental health system have combined to create an evidence-based climate of realistic optimism. Progressive neuroscientific advances hold out the strong possibility of more definitive biological treatments in the near future. However, this improved potential for better outcomes and quality of life for people with schizophrenia has not been translated into reality in Australia. The efficacy-effectiveness gap is wider for schizophrenia than any other serious medical disorder. Therapeutic nihilism, under-resourcing of services and a stalling of the service reform process, poor morale within specialist mental health services, a lack of broad-based recovery and life support programs, and a climate of tenacious stigma and consequent lack of concern for people with schizophrenia are the contributory causes for this failure to effectively treat. These guidelines therefore tackle only one element in the endeavour to reduce the impact of schizophrenia. They distil the current evidence-base and make recommendations based on the best available knowledge. Method: A comprehensive literature review (1990–2003) was conducted, including all Cochrane schizophrenia reviews and all relevant meta-analyses, and a number of recent international clinical practice guidelines were consulted. A series of drafts were refined by the expert committee and enhanced through a bi-national consultation process. Treatment recommendations: This guideline provides evidence-based recommendations for the management of schizophrenia by treatment type and by phase of illness. The essential features of the guidelines are: (i) Early detection and comprehensive treatment of first episode cases is a priority since the psychosocial and possibly the biological impact of illness can be minimized and outcome improved. An optimistic attitude on the part of health professionals is an essential ingredient from the outset and across all phases of illness. (ii) Comprehensive and sustained intervention should be assured during the initial 3–5 years following diagnosis since course of illness is strongly influenced by what occurs in this ‘critical period’. Patients should not have to ‘prove chronicity’ before they gain consistent access and tenure to specialist mental health services. (iii) Antipsychotic medication is the cornerstone of treatment. These medicines have improved in quality and tolerability, yet should be used cautiously and in a more targeted manner than in the past. The treatment of choice for most patients is now the novel antipsychotic medications because of their superior tolerability and, in particular, the reduced risk of tardive dyskinesia. This is particularly so for the first episode patient where, due to superior tolerability, novel agents are the first, second and third line choice. These novel agents are nevertheless associated with potentially serious medium to long-term side-effects of their own for which patients must be carefully monitored. Conventional antipsychotic medications in low dosage may still have a role in a small proportion of patients, where there has been full remission and good tolerability; however, the indications are shrinking progressively. These principles are now accepted in most developed countries. (vi) Clozapine should be used early in the course, as soon as treatment resistance to at leasttwo antipsychotics has been demonstrated. This usually means incomplete remission of positive symptomatology, but clozapine may also be considered where there are pervasive negative symptoms or significant or persistent suicidal risk is present. (v) Comprehensive psychosocial interventions should be routinely available to all patients and their families, and provided by appropriately trained mental health professionals with time to devote to the task. This includes family interventions, cognitive-behaviour therapy, vocational rehabilitation and other forms of therapy, especially for comorbid conditions, such as substance abuse, depression and anxiety. (vi) The social and cultural environment of people with schizophrenia is an essential arena for intervention. Adequate shelter, financial security, access to meaningful social roles and availability of social support are essential components of recovery and quality of life. (vii) Interventions should be carefully tailored to phase and stage of illness, and to gender and cultural background. (viii) Genuine involvement of consumers and relatives in service development and provision should be standard. (ix) Maintenance of good physical health and prevention and early treatment of serious medical illness has been seriously neglected in the management of schizophrenia, and results in premature death and widespread morbidity. Quality of medical care for people with schizophrenia should be equivalent to the general community standard. (x) General practitioners (GPs)s should always be closely involved in the care of people with schizophrenia. However, this should be truly shared care, and sole care by a GP with minimal or no specialist involvement, while very common, is not regarded as an acceptable standard of care. Optimal treatment of schizophrenia requires a multidisciplinary team approach with a consultant psychiatrist centrally involved.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Family psychoeducation is recommended in clinical practice guidelines for psychotic disorders, most notably schizophrenia, in various industrialised countries (Canadian Psychiatric Association 2005;Galletly 2005;Kreyenbuhl 2010;NICE 2014).”
From Family psychoeducation for people living with schizophrenia and their families (2018) · cites this paper as Galletly 2005
Citations
Cites
3 retracted
Assertive community treatment for people with severe mental disorders
Marshall, M., & Lockwood, A. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001089 · Cited by 589
RetractedCase management for people with severe mental disorders
Marshall, M., Gray, A. M., Lockwood, A., & Green, R. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000050 · Cited by 275
RetractedCognitive behaviour therapy for schizophrenia
Jones, C., Cormac, I., Silveira da Mota Neto, J. I., & Campbell, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000524.pub2 · Cited by 269
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,703
Scottish Intercollegiate Guidelines Network
Twaddle, S., & Qureshi, S. (2005) · Evidence-based Healthcare and Public Health · doi:10.1016/j.ehbc.2005.09.008 · Cited by 4,080
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Jorm, A. F., Korten, A. E., Jacomb, P. A., Christensen, H., Rodgers, B., & Pollitt, P. (1997) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1997.tb140071.x · Cited by 2,585
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Research works printed but not linked: 28
- SANE, 2002, Schizophrenia: costs. An analysis of the burden of schizophrenia and related suicide in Australia
- McGlashan T H, 2004, Schizophrenia Research, 67, 164
- Morrison A P, 2004, Schizophrenia Research, 67, 7
- Lieberman J, 1989, Psychopharmacology Bulletin, 25, 92
- Nordentoft M, 2004, Schizophrenia Bulletin, 70, 31
- Bleuler M, 1976, Der Nervenarzt, 47, 477
- Harding C M, 1987, Hospital and Community Psychiatry, 38, 477
- 10.1001/archpsyc.60.6.565 · DOI · Paper page
- National Health Service, 2001, Clinical Standards Board for Scotland: clinical standards for schizophrenia
- National Health Service, 2001, Clinical Standards Board for Scotland: evidence base for clinical standards for schizophrenia
- National Institute for Clinical Excellence, 2002, Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care
- Canadian Psychiatric Association, 1998, Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie Vo, 43, 25S
- Auditor-General-Victoria, 2002, Mental health services for people in crisis
- Mental Health Council of Australia, 2003, Out of hospital, out of mind
- Marshall M, 2004, The Cochrane Library
- Pharoah F, 2004, The Cochrane Library
- Pekkala E, 2004, The Cochrane Library
- Cormac I, 2004, The Cochrane Library
- Hayes R L, 2004, The Cochrane Library
- Robertson L, 2004, The Cochrane Library
- 10.1176/ajp.153.3.321 · DOI · Paper page
- Crowther R, 2004, The Cochrane Library
- Marshall M, 2004, The Cochrane Library
- 10.1192/bjp.173.5.423 · DOI
- 10.1192/bjp.175.6.501 · DOI
- Malmberg L, 2004, The Cochrane Library
- Johannessen J O, 2002, Acta Psychiatrica Scandinavica, 106, 9
- Power P, 1999, The recognition and management of early psychosis: a preventive approach, 338
Cited by
Sorted by citations
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 664
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Siskind, D. J., McCartney, L., Goldschlager, R., & Kisely, S. R. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 646
Early intervention in psychosis: concepts, evidence and future directions
MCGORRY, P. D., KILLACKEY, E., & YUNG, A. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00182.x · Cited by 581
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014
Hayes, J. F., Marston, L., Walters, K., King, M. B., & Osborn, D. P. J. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.117.202606 · Cited by 451
Long-term Follow-up of a Group at Ultra High Risk (“Prodromal”) for Psychosis
Nelson, B., Yuen, H. P., Wood, S. J., Lin, A. P., Spiliotacopoulos, D., Bruxner, A., Broussard, C., Simmons, M. B., Foley, D. L., Brewer, W. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1270 · Cited by 434
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 424
Declining Transition Rate in Ultra High Risk (Prodromal) Services: Dilution or Reduction of Risk?
Yung, A. R., Yuen, H. P., Berger, G. E., Francey, S. M., Hung, T.-C., Nelson, B., Phillips, L., & McGorry, P. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm015 · Cited by 422
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Yung, A. R., Nelson, B., Stanford, C., Simmons, M. B., Cosgrave, E. M., Killackey, E., Phillips, L. J., Bechdolf, A., Buckby, J., & McGorry, P. D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.012 · Cited by 358
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
Defining "elderly" in clinical practice guidelines for pharmacotherapy
Singh, S., & Bajorek, B. V. (2014) · Pharmacy Practice · doi:10.4321/s1886-36552014000400007 · Cited by 324
First-Episode Psychosis: Psychopathology, Quality of Life, and Functional Outcome
MALLA, A. K. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi031 · Cited by 284
Age differences in mental health literacy
Farrer, L. M., Leach, L., Griffiths, K. M., Christensen, H. M., & Jorm, A. F. (2008) · BMC Public Health · doi:10.1186/1471-2458-8-125 · Cited by 288
Recovery from Mental Illness as an Emergent Concept and Practice in Australia and the UK
Ramon, S., Healy, B., & Renouf, N. (2007) · International Journal of Social Psychiatry · doi:10.1177/0020764006075018 · Cited by 276
Álvarez‐Jiménez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp129 · Cited by 248
Laws, K. R., Darlington, N., Kondel, T. K., McKenna, P. J., & Jauhar, S. (2018) · BMC Psychology · doi:10.1186/s40359-018-0243-2 · Cited by 244
The interface of physical and mental health
Doherty, A. M., & Gaughran, F. (2014) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-014-0847-7 · Cited by 237
Hert, M. A. F. D., Vancampfort, D., Correll, C. U., Mercken, V., Peuskens, J., Sweers, K., van Winkel, R., & Mitchell, A. J. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084665 · Cited by 226
Antipsychotic Polypharmacy in Schizophrenia
Barnes, T. R. E., & Paton, C. (2011) · CNS Drugs · doi:10.2165/11587810-000000000-00000 · Cited by 194
McGorry, P., Killackey, E., & Yung, A. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01327.x · Cited by 224
Diabetes mellitus and severe mental illness: mechanisms and clinical implications
Holt, R. I. G., & Mitchell, A. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.203 · Cited by 189
Stain, H. J., Galletly, C. A., Clark, S., Wilson, J., Killen, E. A., Anthes, L., Campbell, L. E., Hanlon, M.-C., & Harvey, C. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412449060 · Cited by 178
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia
Fleischhacker, W. W., & Uchida, H. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000399 · Cited by 182
Carter, G., Page, A., Large, M., Hetrick, S., Milner, A. J., Bendit, N., Walton, C., Draper, B., Hazell, P., Fortune, S., et al. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416661039 · Cited by 167
Jorm, A. F., & Wright, A. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449179 · Cited by 159
Mojtabai, R., Fochtmann, L. J., Chang, S.-W., Kotov, R., Craig, T., & Bromet, E. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp045 · Cited by 167
Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., Tso, S., Pang, E. P. F., Chan, K. T., Wong, Y. C., et al. (2010) · BMJ · doi:10.1136/bmj.c4024 · Cited by 151
Pillinger, T., Howes, O. D., Correll, C. U., Leucht, S., Huhn, M., Schneider‐Thoma, J., Gaughran, F., Jauhar, S., McGuire, P. K., Taylor, D. M., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00262-6 · Cited by 149
Killackey, E. J., Jackson, H. J., Gleeson, J., Hickie, I. B., & McGorry, P. D. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2006.01918.x · Cited by 148
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1009163 · Cited by 147
Hui, C. L. M., Honer, W. G., Lee, E. H. M., Chang, W. C., Chan, S. K. W., Chen, E. S. M., Pang, E. P. F., Lui, S. S. Y., Chung, D. W. S., Yeung, W. S., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30090-7 · Cited by 149
Kettle, J. W. L., O'Brien-Simpson, L., & Allen, N. B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.011 · Cited by 134
Salisbury, T. T., Killaspy, H. T., Wright, C., Turton, P., White, S. J., Kallert, T. W., Schuster, M., Cervilla, J. A., Brangier, P., Raboch, J., et al. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-55 · Cited by 134
Effectiveness of early intervention in psychosis
Killackey, E. J., & Yung, A. R. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328017f67d · Cited by 133
The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome
Woods, S. W., Walsh, B. C., Saksa, J. R., & McGlashan, T. H. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.012 · Cited by 130
Happell, B., Scott, D. S., Platania‐Phung, C., & Nankivell, J. (2012) · International Journal of Mental Health Nursing · doi:10.1111/j.1447-0349.2011.00799.x · Cited by 127
Ramesh, T., Igoumenou, A., Montes, M. V., & Fazel, S. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.02.007 · Cited by 126
Correll, C. U., & Gallego, J. A. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.06.007 · Cited by 125
Crawford, M., Jayakumar, S., Lemmey, S. J., Zalewska, K., Patel, M. X., Cooper, S. J., & Shiers, D. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.142521 · Cited by 124
Ruggeri, M., Bonetto, C., Lasalvia, A., Fioritti, A., de Girolamo, G., Santonastaso, P., Pileggi, F., Neri, G., Ghigi, D., Giubilini, F., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv058 · Cited by 123
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
The social return on investment model: a systematic literature review
Corvo, L., Pastore, L., Mastrodascio, M., & Cepiku, D. (2022) · Meditari Accountancy Research · doi:10.1108/medar-05-2021-1307 · Cited by 111
Quantifying Clinical Relevance in the Treatment of Schizophrenia
Correll, C. U., Kishimoto, T., Nielsen, J., & Kane, J. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.016 · Cited by 111
Stigmatization as an Environmental Risk in Schizophrenia: A User Perspective
van Zelst, C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn184 · Cited by 109
Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
McIlwain, M., Anderson, V. M., Pillai, A., Kydd, R. R., & Russell, B. R. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu117 · Cited by 104
Wood, S. J., Yung, A. R., McGorry, P. D., & Pantelis, C. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.05.034 · Cited by 110
The CATIE and CUtLASS Studies in Schizophrenia
Naber, D., & Lambert, M. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00002 · Cited by 109
Recruitment and Treatment Practices for Help-Seeking "Prodromal" Patients
McGlashan, T. H., Addington, J., Cannon, T. D., Heinimaa, M., McGorry, P. D., O’Brien, M. P., Penn, D. L., Perkins, D. O., Salokangas, R. K. R., Walsh, B., et al. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm025 · Cited by 105
Saravane, D., Fève, B., Francès, Y., Corruble, E., Lançon, C., Chanson, P., Maison, P., Terra, J.-L., & Azorin, J. (2009) · L Encéphale · doi:10.1016/j.encep.2008.10.014 · Cited by 105
Evidence-based pharmacotherapy of schizophrenia
Leucht, S., Heres, S., Kissling, W., & Davis, J. M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001380 · Cited by 104
Schizoaffective disorder–an ongoing challenge for psychiatric nosology
Jäger, M., Haack, S., Becker, T., & Frasch, K. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.03.010 · Cited by 98
Guide to the Management of Clozapine-Related Tolerability and Safety Concerns
Citrome, L., McEvoy, J. P., & Saklad, S. R. (2016) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/1935-1232.10.3.163 · Cited by 105
Dellazizzo, L., Potvin, S., Phraxayavong, K., & Dumais, A. (2021) · Schizophrenia · doi:10.1038/s41537-021-00139-2 · Cited by 100
Prediction of psychosis: setting the stage
Yung, A. R., & McGorry, P. D. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.191.51.s1 · Cited by 98
An integrative review of paternal depression
Edward, K.-L., Castle, D., Mills, C., Davis, L., & Casey, J. (2015) · American Journal of Men's Health · doi:10.1177/1557988314526614 · Cited by 122
Vitry, A. I., & Zhang, Y. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb02079.x · Cited by 96
The heart of the matter: cardiometabolic care in youth with psychosis
Curtis, J., Newall, H. D., & Samaras, K. (2012) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2011.00315.x · Cited by 95
Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs
Tarsy, D., Lungu, C., & Baldessarini, R. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00043-4 · Cited by 95
A review of the use of clozapine levels to guide treatment and determine cause of death
Stark, A., & Scott, J. G. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412438871 · Cited by 94
Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management
Holt, R. I. G., & Peveler, R. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03814.x · Cited by 92
Workplace risk factors for anxiety and depression in male-dominated industries: a systematic review
Battams, S., ROCHE, A. M., Fischer, J. A., Lee, N., Cameron, J., & Kostadinov, V. (2014) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2014.954579 · Cited by 103
Packages of Care for Schizophrenia in Low- and Middle-Income Countries
Mari, J. D. J., Razzouk, D., Thara, R., Eaton, J., & Thornicroft, G. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000165 · Cited by 91
Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review
Bozzatello, P., Bellino, S., & Rocca, P. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00067 · Cited by 89
Lambert, M., Conus, P., Cotton, S., Robinson, J., McGorry, P. D., & SCHIMMELMANN, B. G. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f058a0 · Cited by 87
Community Treatment Orders: International Comparisons
Dawson, J. (2005) · Otago University Research Archive (University of Otago) · Cited by 87
Should a “Risk Syndrome for Psychosis” be included in the DSMV?
Yung, A. R., Nelson, B., Thompson, A. D., & Wood, S. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.017 · Cited by 85
MALLA, A. K., Joober, R., Iyer, S. N., Norman, R. M. G., Schmitz, N., Brown, T. G., Lutgens, D., Jarvis, E., Margolese, H. C., Casacalenda, N., et al. (2017) · World Psychiatry · doi:10.1002/wps.20456 · Cited by 85
Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients
Chadda, R. K., Ramshankar, P., Deb, K. S., & Sood, M. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.114596 · Cited by 85
Farhall, J., Greenwood, K. M., & Jackson, H. J. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2006.12.002 · Cited by 118
Doan, T. N., Lennox, N. G., Gomez, M. T., & Ware, R. S. (2013) · Journal of Intellectual & Developmental Disability · doi:10.3109/13668250.2013.778968 · Cited by 79
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 81
Haddad, P. M., Das, A., Keyhani, S., & Chaudhry, I. B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111424929 · Cited by 81
Outcomes for schizophrenia patients with clozapine treatment: how good does it get?
Wheeler, A., Humberstone, V., & Robinson, G. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093588 · Cited by 70
Robson, D., & Haddad, M. (2011) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2011.07.011 · Cited by 70
Schizophrenia guidelines across the world: A selective review and comparison
Gäebel, W., Riesbeck, M., & Wobrock, T. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.606801 · Cited by 73
Paterson, C., Karatzias, T., Dickson, A., Harper, S., Dougall, N., & Hutton, P. (2018) · British Journal of Clinical Psychology · doi:10.1111/bjc.12182 · Cited by 69
Teasdale, S. B., Ward, P. B., Rosenbaum, S., Watkins, A., Curtis, J., Kalucy, M., & Samaras, K. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114516001033 · Cited by 69
Augmentation with antidepressants in schizophrenia treatment: benefit or risk
Zhang, M., & Mao, Y. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s62266 · Cited by 65
Harvey, C. A., & O’Hanlon, B. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413476754 · Cited by 64
Happell, B., Scott, D. S., Nankivell, J., & Platania‐Phung, C. (2013) · Journal of Clinical Nursing · doi:10.1111/j.1365-2702.2012.04325.x · Cited by 64
Gleeson, J., Cotton, S., Álvarez‐Jiménez, M., Wade, D., Gee, D., Crisp, K., Pearce, T., Spiliotacopoulos, D., Newman, B., & McGorry, P. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr165 · Cited by 66
Clozapine’s Role in the Treatment of First-Episode Schizophrenia
Remington, G. J., Agid, O., Foussias, G., Hahn, M., Rao, N. P., & Sinyor, M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12060778 · Cited by 63
The experiences of basic body awareness therapy in patients with schizophrenia
Hedlund, L., & Gyllensten, A. L. (2009) · Journal of Bodywork and Movement Therapies · doi:10.1016/j.jbmt.2009.03.002 · Cited by 62
Profession Differences in Family Focused Practice in the Adult Mental Health System
Maybery, D. J., Goodyear, M. J., O’Hanlon, B., Cuff, R., & Reupert, A. (2014) · Family Process · doi:10.1111/famp.12082 · Cited by 62
Forgotten family members: the importance of siblings in early psychosis
Bowman, S., Álvarez‐Jiménez, M., Wade, D., McGorry, P. D., & Howie, L. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12068 · Cited by 70
Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison
Roh, D. D., Chang, J.-G., Kim, C., Cho, H. S., An, S. K., & Jung, Y. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413488221 · Cited by 61
Nurses' views on physical activity for people with serious mental illness
Happell, B., Scott, D., Platania‐Phung, C., & Nankivell, J. (2012) · Mental health and physical activity · doi:10.1016/j.mhpa.2012.02.005 · Cited by 55
Long-Acting Formulations of Atypical Antipsychotics
Chue, P. S., & Emsley, R. A. (2007) · CNS Drugs · doi:10.2165/00023210-200721060-00001 · Cited by 59
Morrison, P., Meehan, T., & Stomski, N. J. (2014) · International Journal of Mental Health Nursing · doi:10.1111/inm.12110 · Cited by 65
Dodd, K., Duffy, S., Stewart, J. A., Impey, J., & Taylor, N. F. (2010) · Disability and Rehabilitation · doi:10.3109/09638288.2010.526162 · Cited by 58
Interventions to reduce antipsychotic polypharmacy: A systematic review
Tani, H., Uchida, H., Suzuki, T., 藤井, 康., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.015 · Cited by 58
Lambert, T., Reavley, N. J., Jorm, A. F., & Browne, M. A. O. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416686693 · Cited by 58
Where to Position Clozapine: Re-Examining the Evidence
Agid, O., Foussias, G., Singh, S., & Remington, G. J. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005501007 · Cited by 57
Can positive family factors be protective against the development of psychosis?
González-Pinto, A. M., de Azúa, S. R., Ibáñez, B., Cuesta, S. O., Castro‐Fornieles, J., Graell-Berna, M., Ugarte, A., Parellada, M., Moreno, D. M., Soutullo, C. A., et al. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.05.015 · Cited by 56
The meaning of recovery in a regional mental health service: an action research study
Kidd, S., Kenny, A. J., & McKinstry, C. (2014) · Journal of Advanced Nursing · doi:10.1111/jan.12472 · Cited by 54
Lin, C.-C., Wang, Y.-C., Chen, J., Liou, Y., Bai, Y., Lai, I., Chen, T., Chiu, H., & Li, Y. (2008) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2008.02.004 · Cited by 54
Farhall, J., Freeman, N. C., Shawyer, F., & Trauer, T. (2009) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.2009.tb00456.x · Cited by 51
Metadata
- Authors
- Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders
- Corresponding author
- Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 39
- Issue
- 1-2
- Pages
- 1-30
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W3115493962
- Cited by
- 435
- References
- 207
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 9 · 2019: 9 · 2018: 17 · 2017: 21 · 2016: 29 · 2015: 30 · 2014: 35 · 2013: 38 · 2012: 30
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- schizophrenia, antipsychotic drugs, first-episode psychosis, early intervention, psychosocial interventions, social skills training, cognitive behavioral therapy, relapse prevention, medication adherence, treatment-resistant schizophrenia, atypical antipsychotics, mental health service reform, efficacy-effectiveness gap, stigma, recovery programs, evidence-based treatment
- MeSH terms
- Australia, Combined Modality Therapy, Follow-Up Studies, Humans, New Zealand, Psychotic Disorders, Rehabilitation, Vocational, Schizophrenia, Schizophrenic Psychology, Socioenvironmental Therapy, Antipsychotic Agents, Evidence-Based Medicine, Early Diagnosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review